Racura Oncology LtdASX: RAC

Racura Oncology Adelaide Investor Briefing

· Issued by Racura Oncology Ltd via ASX

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Racura Oncology Ltd has announced an investor briefing in Adelaide, inviting interested investors to attend on a specified date. The briefing will be hosted by Managing Director and CEO Dr. Daniel Tillett, providing updates on the company's clinical programs. The company is advancing its lead asset, (E,E)-bisantrene, through various clinical trials targeting multiple oncology indications.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/racura-oncology-adelaide-investor-briefing

Release

Racura Oncology Ltd | ABN 61 149 318 749 | L36 1 Macquarie Place Sydney NSW 2000 Australia +61 2 8051 3043 | info@racuraoncology.com | www.racuraoncology.com 1 ASX Announcement Racura Oncology Adelaide Investor Brie fi ng 4 September 2026 Racura Oncology Ltd (“Racura” or the...

Racura Oncology Ltd on 6ix

Earlier from Racura Oncology

Later from Racura Oncology

All Racura Oncology news releases